Amarin (AMRN) reported $214M in revenue for fiscal 2025, −6.5% year on year. That ranks #2638 by revenue among 2853 SEC filers and #280 in Healthcare. It posted a net loss of −$38.8M for the same year. Revenue has grown 19.1% a year on average since 2013 ($26.4M then). The fiscal 2025 balance sheet shows $671M in total assets, $135M in cash and $49.7M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $214M | −6.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $121M | +48.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$50.2M | +$41.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$38.8M | +$48.2M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $6.7M | +$37.7M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $252,000 | −89.8% | FY20202020-12-31 |
| Total assetsAssets | $671M | −2.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $459M | −5.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $135M | +11.3% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $49.7M | +7.8% | FY20192019-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $45.1M | −$10.5M | Open → |
| Q2 20262026-06-30 | $42.2M | −$7.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Amarin Corp PLC
- Ticker
- AMRN
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000897448
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 29, 2026Open filing →
- 10-KMar 2, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AxogenAXGN | $225M | −$15.7M |
| Ideaya BiosciencesIDYA | $219M | −$114M |
| Vanda PharmaceuticalsVNDA | $216M | −$221M |
| AmarinAMRN | $214M | −$38.8M |
| Treace Medical ConceptsTMCI | $213M | −$59.0M |
| Establishment LabsESTA | $211M | −$51.1M |
| Canopy GrowthCGC | $204M | −$189M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Amarin — Key figures |url=https://companiesranked.com/en/company/amarin |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Amarin — Key figures. CompaniesRanked. https://companiesranked.com/en/company/amarinBibTeX
@misc{companiesranked-en-company-amarin-2026,
author = {{CompaniesRanked}},
title = {{Amarin — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/amarin}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-085818 · March 2, 2026
{{cite web |title=Amarin — Key figures — 10-K (0001193125-26-085818) |url=https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.